SUMMARY In vitro morphological and functional studies were carried out on platelets which had been cryopreserved in the presence of 5% dimethyl sulphoxide (DMSO). Overall loss of platelets was around 50%. Those which survived freezing and reconstitution showed marked morphological deterioration, increase of procoagulant activity (PF3a) and a decrease in their aggregability and adenine nucleotide content. We conclude that if transfused, cryopreserved platelets are likely to be less effective than fresh platelets and may activate coagulation in vivo and that they should only be used when suitable fresh platelets are not available.
Thrombocytopenia resulting from bone marrow depression is a frequent complication of the newer chemotherapeutic regimens used in the management of haematological malignancies. To minimise the risks of haemorrhagic complications in such cases, supportive therapy in the form of prophylactic platelet infusions is advisable. The increased demand for platelet concentrates has highlighted a number of complications with this type of therapy. Firstly, the rapid deterioration of viability of stored platelets leads to considerable wastage and sometimes to difficulty in meeting demands at weekends and during holiday periods. Secondly, since most platelet infusions are given without cross-matching for HLA-groups at least, the continued effectiveness of such therapy may be compromised by the development of antiplatelet antibodies by the recipient.
To overcome these problems the preparation and use of frozen platelets has been suggested' since this would prolong the storage time sufficiently to enable a bank of HLA-typed platelets to be established and may, in some instances, enable a store of autologous platelets to be laid down during a patient's remission, ready for use should they be required during any subsequent relapse.2 Various freezing procedures have been used and the subject has been recently reviewed.3 While there is no generally approved methodology the use of dimethyl sulphoxide (DMSO) as a cryoprotectant appears to be more widely used than glycerol or other substances.
Platelet freezing programmes are currently being Accepted for publication 18 January 1982 pursued at a number of centres throughout the world, but in many cases the efficacy of the product is determined either empirically or by using tests, the predictive value of which is difficult to establish. Moreover, few if any attempts are made to protect the recipients against the prothrombotic consequences of infusing large numbers of damaged or even disrupted cells.4
In this study we have assessed the in vitro platelet function of frozen platelet concentrates in a number of ways in order both to determine the extent of the damage caused by freezing and as a form of quality control for the procedures involved in platelet cryopreservation.
Material and methods

PREPARATION OF FROZEN PLATELETS
The method used was basically that described previously2 with minor modifications recommended by other workers to improve the viability of the product. Venous blood was anticoagulated with one tenth volume of citrate-phosphate dextrose (CPD), prepared according to Dacie and Lewis' in plastic bottles or bags. The blood was centrifuged immediately at 22°C for 15 min at 150 g. The platelet-rich plasma (PRP) was removed and one tenth volume of acid citrate dextrose (ACD) was added to lower the pH to around 6-8. The PRP and the residual blood were recentrifuged at 22°C for 15 The platelet concentrates were placed in a 37°C water bath until they had just thawed (about 5 min). For functional studies, the suspensions were washed to remove the DMSO, using a combined centrifugation-gel filtration method6 but without adenosine and were resuspended in an equal volume of CPD-PPP.
At each stage in the above process an aliquot of the platelet suspension was set aside for platelet count and for functional and morphological studies.
PLATELET FUNCTION TESTS
Platelet counts were performed by the method of Brecher and Cronkite7 and platelet aggregation by the turbidometric method.8 Platelet-rich plasma (0.45 ml) was stirred at 1000 rpm in an aggregometer at 37°C with 0*05 ml of either adenosine diphosphate (ADP), adrenaline (Sigma) collagen suspension (Horm-Chemie) or Ristocetin (Lundbeck). After three minutes, the fall in the optical density (OD) of the PRP was measured and expressed as a percentage of the OD difference between PRP and PPP.9 For ADP, the extent of the primary wave was also determined by measuring the fall in OD of PRP one minute after addition of the agonist.
Platelet factor 3 availability (PF3a) was measured by a modification of the method of Spaet and Cintron'°in which the Stypven time of PRP is measured either directly or after incubation of PRP for 20 min at 37°C with kaolin and quantified by comparison with the Stypven time of PRP in which the platelets have been completely disrupted by repeated freez- Results in parentheses are the % aggregation one minute after addition of ADP. There was no significant difference in platelet aggregability between blood anticoagulated with CPD or with 3-8% trisodium citrate. Because low pH ACD or DMSO completely abolish platelet aggregation, these substances had to be removed by washing before functional studies could be carried out. Table 1 compares the aggregation responses after washing, of ACD-PRP or DMSO-treated PRP, with and without freezing/thawing, with those of fresh CPD-PRP. Only the freezing and thawing process had any permanent inhibitory effect on aggregability. Responses using ADP or adrenaline as agonist were particularly affected, and with ADP especially, the initial rate of aggregation was decreased.
PLATELET FACTOR 3 AVAILABILITY (TABLE 2) Basal levels (no kaolin) of PF3a in washed ACD-PRP and DMSO-PRP were only marginally higher than those in the original CPD-PRP and the additional amounts generated on incubation with kaolin were also similar. In contrast, markedly increased basal PF3a levels were found in washed, cryopreserved platelets and little or no further rise could be induced by kaolin activation.
PLATELET ADENINE NUCLEOTIDES (TABLE 3) Nucleotide concentrations were similar at all stages prior to freezing. However, cryopreservation resulted in a statistically significant decrease (p < 0-02) in ATP and ADP concentrations although levels were still within the normal range.
MORPHOLOGICAL STUDIES
Compared to freshly fixed platelets (Fig. a) , those which had been processed to the DMSO stage before fixation often showed some loss of discoid shape with moderate vacuolation (Fig. b) , the latter probably being due to dilatation of the open canalicular system. Even when the normal discoid shape was maintained during this stage it was lost on subsequent cryopreservation when more marked morphological changes were invariably observed (Fig. c) . Plasma membrane damage after freezing was particularly obvious, many cells having a fuzzy outline with numerous large pseudopods devoid of granules. The cell granule complement, including dense bodies, appeared to be relatively normal however.
Discussion
The present study shows that platelets cryopreserved in 5% DMSO using existing methodology, exhibited marked morphological and functional abnormalities. Alterations in the plasma membrane of the platelets were clearly visible in electron micrographs and were associated with the development of a potent, phospholipid-related procoagulant activity, referred to as PF3.
The ability of cryopreserved platelets to undergo the normal aggregation responses to physiological agonists such as ADP and collagen, upon which in vivo platelet plug formation depends, was also impaired. This was probably related to the plasma membrane changes since primary aggregation which depends on surface-related events, was particularly inhibited whereas the granule content and the releasable pool of adenine nucleotides through which secondary aggregation is mediated, were relatively unaffected.
Practically all of these disturbances were due to the freezing-thawing step since only minimal changes were induced by DMSO or by the washing procedure used to remove the cryoprotectant.
Morphological abnormalities similar to those described above have been published previously'2 13 but because of the technical difficulties of applying to cryopreserved platelets the tests routinely used to evaluate platelet function, these have been rejected by other workers in favour of tests which, though simpler to perform, may be of more questionable physiological significance. For example, serotonin (5HT) uptake by platelets has been advocated by some,'4 15 despite the fact that since this property is retained by isolated platelet dense bodies'6 it cannot be regarded as a measure of the cell's intactness. Similarly, the hypotonic shock response of cryopreserved platelets may not always correlate with platelet survival.'7
Whatever the methods used to assess in vitro the viability of cryopreserved platelets the almost universal conclusion has been that they respond markedly less well than fresh platelets. Clearly, however, the critical test is their ability to circulate, survive and function normally when reinfused. Several studies have shown a modest clinical improvement associated with an increment in the platelet count in recipients of cryopreserved platelets. However, the platelet recovery rates have been extremely variable and rarely more than half those achieved with fresh platelets, even though the platelets which do remain in the circulation may have a close to normal survival. In vivo functional studies have often been uncontrolled or evaluated subjectively, or in some instances, omitted altogether. Partial correction of the bleeding time has been noted2 but where it has been possible to recalculate the data applying the formula developed by Harker and Slichter'1 which relates bleeding time to platelet count, the shortening was almost invariably less than expected.
In addition to these iatrogenic functional abnormalities, some types of leukaemia are associated with intrinsic platelet defects which may persist during remission and these will further limit the value of frozen autologous platelet infusions in such cases.
Finally, scant attention has been paid to the possibility of inducing a hypercoagulable state by transfusing large numbers of damaged cells. Although no cases of clinically overt thrombotic sequelae has been reported, Odink and Brand14 noted an increase in fibrinopeptide A level in one of seven patients studied following infusion of cryopreserved platelets derived from approximately one unit of blood.
Thus we believe that the low functional activity of cryopreserved platelets coupled with the expensive and time-consuming manoeuvres involved in their production argue against their use for purposes of simple expediency and that they should only be used when transfusion of compatible platelets might be life-saving and suitable fresh platelets are not available. 
